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Diagnostic Hematology 
Pediatric B-cell Lymphoma, Unclassifiable, With 
Intermediate Features Between Those of Diffuse Large 
B-cell Lymphoma and Burkitt Lymphoma: A Report of 
Two Cases
Shanxiang Zhang, M.D.1, David Wilson, M.D.2, and Magdalena Czader, M.D.1
Department of Pathology and Laboratory Medicine1, Indiana University; AmeriPath2, Indianapolis, IN, USA
B-cell lymphoma, unclassifiable, with intermediate features be-
tween those of diffuse large B-cell lymphoma (DLBCL) and 
Burkitt lymphoma (BL; intermediate BL/DLBCL) commonly ex-
hibits a morphology similar to that of typical BL and an atypical 
immunophenotype such as diffuse and moderate-to-strong 
BCL2 positivity and/or a Ki67 proliferation index <90%. Alterna-
tively, the tumor cells exhibit greater variations in nuclear size 
and contouring than would be considered acceptable for BL [1, 
2]. Intermediate BL/DLBCL is most commonly observed in adults 
[3-5]. Among pediatric populations, to date, the English literature 
only includes reports of one case of intermediate BL/DLBCL in a 
2-yr-old Korean boy and eight cases in Chinese children [6, 7]. 
Here, we report two additional cases that represent the first re-
port from a western population.
Case 1
A 15-yr-old girl with sudden-onset abdominal pain and emesis 
was found to have a small bowel obstruction and intussuscep-
tion during a computed tomography (CT) study. An urgent ex-
ploratory laparotomy revealed a mass comprising mildly to mod-
erately pleomorphic lymphoid cells that were mostly medium-
sized with rare large cells and slightly irregular nuclear contours; 
these cells primarily contained 2-3 inconspicuous nucleoli or, 
occasionally, single prominent nucleoli. Mitotic figures were fre-
quent. Focally, tingible body macrophages imparted a “starry 
sky” appearance. The atypical lymphoid cells were positive for 
CD20, CD10, BCL-6 (focal, weak), MUM-1, and BCL-2 and neg-
ative for terminal deoxynucleotidyl transferase (TdT). The prolif-
erative index, as indicated by Ki-67 staining, was high (>90%; 
Fig. 1). An Epstein-Barr virus (EBV) study with late membrane 
protein 1 (LMP1) immunohistochemical stain (IHC) and in situ 
hybridization for EBV-encoded RNAs (EBER), flow cytometric 
analysis, and karyotyping were not performed. FISH analysis re-
vealed MYC rearrangement but no BCL2 or BCL6 rearrangement 
or copy number changes. Three of the 16 resected lymph nodes 
were also positive for intermediate BL/DLBCL. The patient under-
went chemotherapy with cyclophosphamide, vincristine, predni-
sone, doxorubicin, and methotrexate. She remained in complete 
remission 11 months after completing chemotherapy.
Case 2
A 4-yr-old boy with a 2-week history of abdominal distension and 
Received: January 8, 2014
Revision received: February 15, 2014
Accepted: November 25, 2014
Corresponding author: Shanxiang Zhang
Department of Pathology and Laboratory Medicine,
Indiana University, 350 West 11th Street, Room 5042,
Indianapolis, IN 46202, USA
Tel: +1-317-491-6175, Fax: +1-317-491-6114, E-mail: sz5@iupui.edu
© The Korean Society for Laboratory Medicine.
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Zhang S, et al.
Intermediate pediatric B-cell lymphoma 
http://dx.doi.org/10.3343/alm.2015.35.2.254 www.annlabmed.org  255
diarrhea was found to have diffuse bowel wall thickening on CT. 
A transrectal biopsy revealed a diffuse infiltrate of predominantly 
medium-sized with rare large atypical lymphoid cells; these cells 
had slightly irregular nuclear contours, vesicular chromatin, and 
mostly inconspicuous nucleoli. Apoptotic bodies and mitotic fig-
ures were frequently observed. The atypical lymphoid cells were 
positive for CD20, PAX-5, CD10, BCL-6, and BCL-2 and exhib-
ited a high proliferative index, as indicated by Ki-67 staining (> 
95%). MUM-1 staining was negative. The EBV study was nega-
tive according to LMP1 IHC and EBER in situ hybridization. Con-
current flow cytometric analysis revealed a monoclonal B-cell 
population with CD19, CD20, CD22, CD10, and surface kappa 
light-chain expression. The monoclonal B cells were negative for 
CD5, CD23, CD34, and TdT. A cytogenetic analysis (karyotyping) 
was not performed. FISH analysis with a MYC dual-color break 
apart probe revealed MYC rearrangement. There was no evi-
dence of BCL2/IGH fusion, BCL6 rearrangement, or copy num-
ber changes in BCL2 or BCL6. The bone marrow and central 
nervous system were not involved (stage III). This patient re-
ceived the same chemotherapy regimen as patient 1 and re-
mained in remission for 12 months, as per the last follow-up.
 We conducted a systematic review of the pediatric high-grade 
Fig. 1. Morphologic (A, Hematoxylin and eosin staining, ×50) and immunophenotypic (B-F, ×20) features of B-cell lymphoma, unclassifi-
able, with intermediate features between DLBCL and Burkitt lymphoma. (B) CD20, (C) BCL-6, (D) BCL-2, (E) MUM-1, and (F) Ki-67. 
A
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Table 1. Comparison of the current cases with previously reported intermediate BL/DLBCL cases in English literature
Case No.
Sex 
(N)
Age 
(yr)
Tissue /
Location 
(Case No.)
Immunophenotype*
FISH for gene rearrangement*
EBER* Karyotype c-MYC BCL2 BCL6 Follow-up
Ahn et al. [6] 1 M 2 Femur neck (1) CD20, CD10, BCL6, MUM1 (not 
mentioned), BCL2, Ki-67 (-90%)
0/1 Complex 1/1 0/1 0/1 died at 5 months
Lu et al. [7] 8 M (6), 
F (2)
4-13 Abdomen/
intestine (7), 
gingiva (1)
CD20 (8/8), CD10 (6/8), BCL6 (5/8), 
MUM1 (5/8), BCL2 (4/8), Ki-67 
(60-95%)
6/6 ND 4/8 0/8 0/8† NA
Current study 2 M (1), 
F (1)
4, 15 Intestine (2) CD20 (2/2), CD10 (2/2), BCL6 
(1 strong, 1 weak), MUM1 (1/2), 
BCL2 (2/2), Ki-67 (90%, 95%) 
1/1 ND 2/2 0/2 0/2 remission at 
11, 12 months
*positive case number/tested case number; †2 out of 8 cases showed 3 copies of BCL6.
Abbreviations: DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; M, male; F, female; ND, not done; NA, not available; EBER, in situ hybridization 
for Epstein-Barr virus-encoded RNAs.
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mature B-cell lymphoma cases in our archives from 1988 to 
2012 and identified 2 cases of intermediate BL/DLBCL. Both 
cases exhibited histologic morphology compatible with BL but 
with moderate-to-strong BCL-2 expression. Weak BCL-2 expres-
sion might be observed in BL [2]. In our experience, BCL-2 
staining has yielded consistently negative or weakly positive (few 
cells) results in cases of BL. In addition, Case 1 exhibited focal 
and weak BCL6 expression and moderate-to-strong MUM-1 ex-
pression, which would be unusual for a diagnosis of BL [2]. The 
focal and weak BCL6 staining in Case 2 was not likely caused 
by poor tissue preservation and/or the stain itself, as the staining 
of samples from the same tissue block for other nuclear mark-
ers (MUM-1 and Ki-67) was successful. To the best of our knowl-
edge, these two cases represent the first report of pediatric in-
termediate BL/DLBCL in a western population. A comparison of 
the current cases with previously reported pediatric intermediate 
BL/DLBCL cases in Asian populations is summarized in Table 1.
 The current treatments for pediatric BL, DLBCL, and interme-
diate BL/DLBCL are similar [8]. However, treatment for patients 
aged 15-20 yr has been controversial because adolescent 
DLBCL patients fare better when treated with more aggressive 
regimens, compared with those who receive a cyclophospha-
mide, doxorubicin, vincristine, prednisone (CHOP)-like regimen 
[9, 10]. Both of our patients were treated with a BL chemother-
apeutic regimen. It will be interesting to observe the responses 
of our patients, particularly the 15-yr-old female patient, during 
long-term follow-up. With the development of individualized tar-
geted therapies, the recognition of pediatric intermediate BL/
DLBCL might become more clinically relevant. 
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